Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026
Rhea-AI Summary
Resmed (NYSE: RMD) will report second quarter fiscal 2026 financial and operational results on Thursday, January 29, 2026 after NYSE close. Management will host a live webcast discussing results and other forward-looking material at 1:30 p.m. PST / 4:30 p.m. EST (International: London 9:30 p.m. GMT; Sydney Jan 30 8:30 a.m. AEDT).
The webcast is available only at https://investor.resmed.com. A replay will be posted ~two hours after the webcast; a phone replay is available ~three hours after the webcast through February 12, 2026 (Conference ID: 13757750).
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RMD gained 0.62%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RMD slipped 0.39% while key peers showed mixed moves: ALC -1.36%, BDX -1.31%, WST -0.65%, HOLX +0.15%, SOLV +0.59%. This points to stock-specific trading rather than a clear sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Conference participation | Positive | +1.0% | Announcement of presentation at J.P. Morgan Healthcare Conference with webcast access. |
| Dec 08 | FDA clearance news | Positive | -2.5% | FDA clearance for AI-enabled Smart Comfort CPAP comfort settings product launch. |
| Oct 30 | Earnings results | Positive | -0.5% | Reported Q1 FY26 revenue growth, margin expansion, strong EPS and cash flow. |
| Oct 09 | Earnings date notice | Neutral | -2.1% | Announcement of timing and webcast details for Q1 FY26 earnings release. |
| Sep 16 | Conference participation | Positive | -0.3% | Participation announcement for Bank of America Global Healthcare Conference with webcast. |
Recent positive fundamental or regulatory news (earnings, FDA clearance) has often seen muted or negative next-day price reactions, suggesting a tendency toward divergence on good news.
Over the past several months, ResMed reported strong fiscal Q1 2026 results with revenue of $1.336B, gross margin of 61.5%, and diluted EPS of $2.37, alongside dividends and buybacks. The company also received FDA clearance for its AI-enabled Smart Comfort device and remained active at major healthcare conferences. Prior earnings-date announcements similarly detailed webcast logistics. Today’s Q2 FY26 earnings-date notice fits this pattern of routine, informational pre-earnings communication.
Market Pulse Summary
This announcement sets the timetable for ResMed’s Q2 fiscal 2026 earnings release on January 29, 2026, including webcast logistics and replay details. It follows a period of strong reported fundamentals and multiple conference and regulatory updates. Investors may focus on how upcoming results build on prior revenue growth, margin expansion, and digital-therapy initiatives, while also monitoring insider activity and broader sector conditions around the release date.
AI-generated analysis. Not financial advice.
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
| Earnings webcast details: | ||
| • | Location: | https://investor.resmed.com |
| • | Date: | Thursday, January 29, 2026 |
| • | Time: | 1:30 p.m. PST / 4:30 p.m. EST |
| • | International: | London, Thursday, January 29, 2026, 9:30 p.m. GMT |
| Sydney, Friday, January 30, 2026, 8:30 a.m. AEDT | ||
Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from January 29, 2026, until February 12, 2026, at:
- U.S.: +1 877.660.6853
- International: +1 201.612.7415
- Conference ID: 13757750
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
| For investors | For media |
| +1 858.221.3304 | +1 619.510.1281 |
| investorrelations@Resmed.com | news@Resmed.com |
FAQ
When will Resmed (RMD) report Q2 fiscal 2026 results?
What time is the Resmed (RMD) earnings webcast on January 29, 2026?
How can investors access the Resmed (RMD) Q2 2026 earnings call?
When and where will the Resmed (RMD) earnings replay be available?
What phone numbers provide the Resmed (RMD) earnings phone replay?
